Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hironobu Sanada

Showing results (1-10 of 44) with videos related to

Pageof 5
Sort By:
Nihon Rinsho. Japanese Journal of Clinical Medicine|October 22, 2010
[3,4-Dihydroxyphenylacetic acid (DOPAC)]Midori Yatabe, Hironobu Sanada
Nihon Rinsho. Japanese Journal of Clinical Medicine|September 10, 2005
[3,4-Dihydroxyphenyl alanine (DOPA)]Junichi Yatabe, Hironobu Sanada
Nihon Rinsho. Japanese Journal of Clinical Medicine|September 10, 2005
[3,4-Dihydroxyphenylacetic acid (DOPAC)]Midori Sasaki, Hironobu Sanada
Nihon Rinsho. Japanese Journal of Clinical Medicine|October 22, 2010
[3,4-Dihydroxyphenyl alanine (DOPA)]Junichi Yatabe, Hironobu Sanada
Nihon Rinsho. Japanese Journal of Clinical Medicine|September 10, 2005
[3-methoxy-4-hydroxyphenylglycol (MHPG)]Minoru Yoneda, Hironobu Sanada
Nihon Rinsho. Japanese Journal of Clinical Medicine|October 22, 2010
[3-Methoxy-4 -hydroxyphenylglycol (MHPG)]Minoru Yoneda, Hironobu Sanada
Drugs in R&D|September 11, 2014
Dipeptidyl peptidase-4 inhibitor (vildagliptin) improves glycemic control after meal tolerance test by suppressing glucagon releaseAki Okamoto, Hirohide Yokokawa, Hironobu Sanada
Drugs in R&D|June 24, 2016
Changes in Levels of Biomarkers Associated with Adipocyte Function and Insulin and Glucagon Kinetics During Treatment with Dapagliflozin Among Obese Type 2 Diabetes Mellitus PatientsAki Okamoto, Hirohide Yokokawa, Hironobu Sanada, et al.
Current Hypertension Reports|November 9, 2010
Genetics of salt-sensitive hypertensionHironobu Sanada, John E Jones, Pedro A Jose
Nihon Rinsho. Japanese Journal of Clinical Medicine|June 3, 2004
[Involvement of dopamine receptor in the pathogenesis of hypertension and hypertensive target-organ damage]Hironobu Sanada, Junichi Yatabe, Midori Sasaki, et al.
Pageof 5

Showing results (1-10 of 44) with videos related to

Sort By:
Pageof 5
Nihon Rinsho. Japanese Journal of Clinical Medicine|October 22, 2010
[3,4-Dihydroxyphenylacetic acid (DOPAC)]Midori Yatabe, Hironobu Sanada
Nihon Rinsho. Japanese Journal of Clinical Medicine|September 10, 2005
[3,4-Dihydroxyphenyl alanine (DOPA)]Junichi Yatabe, Hironobu Sanada
Nihon Rinsho. Japanese Journal of Clinical Medicine|September 10, 2005
[3,4-Dihydroxyphenylacetic acid (DOPAC)]Midori Sasaki, Hironobu Sanada
Nihon Rinsho. Japanese Journal of Clinical Medicine|October 22, 2010
[3,4-Dihydroxyphenyl alanine (DOPA)]Junichi Yatabe, Hironobu Sanada
Nihon Rinsho. Japanese Journal of Clinical Medicine|September 10, 2005
[3-methoxy-4-hydroxyphenylglycol (MHPG)]Minoru Yoneda, Hironobu Sanada
Nihon Rinsho. Japanese Journal of Clinical Medicine|October 22, 2010
[3-Methoxy-4 -hydroxyphenylglycol (MHPG)]Minoru Yoneda, Hironobu Sanada
Drugs in R&D|September 11, 2014
Dipeptidyl peptidase-4 inhibitor (vildagliptin) improves glycemic control after meal tolerance test by suppressing glucagon releaseAki Okamoto, Hirohide Yokokawa, Hironobu Sanada
Drugs in R&D|June 24, 2016
Changes in Levels of Biomarkers Associated with Adipocyte Function and Insulin and Glucagon Kinetics During Treatment with Dapagliflozin Among Obese Type 2 Diabetes Mellitus PatientsAki Okamoto, Hirohide Yokokawa, Hironobu Sanada, et al.
Current Hypertension Reports|November 9, 2010
Genetics of salt-sensitive hypertensionHironobu Sanada, John E Jones, Pedro A Jose
Nihon Rinsho. Japanese Journal of Clinical Medicine|June 3, 2004
[Involvement of dopamine receptor in the pathogenesis of hypertension and hypertensive target-organ damage]Hironobu Sanada, Junichi Yatabe, Midori Sasaki, et al.
Pageof 5